Bloodstream Infection Clinical Trial
Official title:
Ethanol Locks for the Treatment of Central Venous Line Infections
Ethanol Locks as an Adjunct Treatment for Central Venous Line Infections
Purpose To evaluate the effectiveness of a 70% ethanol lock solution when used as an adjunct
therapy with antibiotics to treat central venous line infections
Study Design Randomized Controlled Trial
Study Protocol Only those patients meeting all inclusion criteria and no exclusion criteria
will be eligible to participate in this study. Once identified, signed informed consent will
be obtained from the patient's guardian and the patient himself/herself depending on age.
Patients will be randomized into 2 groups: Group 1 - those patients who will receive ethanol
lock therapy and Group 2- those patients who will receive placebo therapy in the form of a
heparin lock solution.
Outcome Measures Treatment success as defined by-
- Clearance of the infection as documented by negative blood cultures on day 6 (one day
after completed of lock treatment)
- Preservation of the line at 30 days post treatment (day 35 of the study), this will be
documented by a chart review in CIS and telephone interview to ensure no further growth
from blood cultures or infections
Treatment failure as defined by-
- Clinical worsening during treatment
- Removal of the line due to persistent infection or sepsis
- Recurrence of infection with the same pathogen within 30 days
Ethanol Lock Technique Protocol (adapted from the Children's Hospital Los Angeles)
1. Obtain a 3ml syringe made by the Baystate Pharmacy which will contain either sterile
70% ethanol solution or 10 units/ml heparin flush solution. Randomization into study
groups will be performed by the pharmacy in patient blocks of 10. Treating physician
and nurses will be blinded to patient group assignment. Syringes will be labeled "70%
ethanol/heparin lock Study Solution"
2. Cleanse Hands
3. Use aseptic Technique throughout procedure
4. Clean injection cap/posi-flow cap with alcohol for 30 seconds and let dry
5. Unclamp the catheter and gently flush with normal saline to ensure patency of the
catheter
6. Instill ethanol/heparin lock into the catheter to fill volume
- Broviac Single Lumen 4.2 Fr (ID 0.7) Dose 0.8ml
- Broviac Single Lumen 6.6 Fr (ID 1mm) Dose 0.8ml
- Med-comp Single Lumen Catheter Dose 1.2ml
- Hickman Double Lumen 7 Fr Distal (ID 1mm) Dose 1.2ml
- Hickman Double Lumen 9 Fr Proximal (ID 0.7) Dose 1.2ml
- Med-comp Double Lumen 8 or 10 Fr Dose 1.2ml
- Port-a-cath- Any Port (including priming tubing) Dose 1.9ml
7. Clamp the catheter
8. Label the locked lumen with the provided label so that med is not flushed through the
catheter
9. Let ethanol dwell in catheter continuously for 4 hours
10. When ethanol has dwelled for 4 hours, withdraw and discard the lock solution
11. The above procedure should be repeated daily for 5 consecutive days
12. The above procedure should be repeated to each lumen of the central venous catheter
daily if there are multiple lumens
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Completed |
NCT02400268 -
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
|
Phase 3 | |
Recruiting |
NCT04070820 -
Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
|
||
Completed |
NCT03147807 -
BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU
|
N/A | |
Completed |
NCT05411315 -
Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment
|
N/A | |
Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
Terminated |
NCT04250168 -
Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
|
||
Terminated |
NCT04876430 -
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
|
Phase 2/Phase 3 | |
Completed |
NCT03255759 -
Actionable Results: Bloodstream Infection Molecular Assay Evaluation
|
N/A | |
Active, not recruiting |
NCT03744728 -
Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures
|
N/A | |
Recruiting |
NCT04839653 -
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
|
N/A | |
Recruiting |
NCT03896893 -
Neonatal Bacterial Colonization Study
|
N/A | |
Completed |
NCT05277350 -
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT00467272 -
Catheter Related - Gram Positive Bloodstream Infections
|
Phase 2 | |
Recruiting |
NCT04658017 -
GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection
|
N/A | |
Completed |
NCT04710212 -
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
|
||
Not yet recruiting |
NCT06271031 -
Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection
|
||
Not yet recruiting |
NCT03991793 -
Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections
|
||
Completed |
NCT00870623 -
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
|